Xiamen Amoytop Biotech Co. Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003RT3
CNY
81.78
1.45 (1.81%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared Positive results for the last 18 consecutive quarters

  • NET SALES(9M) At CNY 2,289.64 MM has Grown at 32.13%
  • NET PROFIT(9M) At CNY 705.37 MM has Grown at 47.07%
  • RAW MATERIAL COST(Y) Fallen by -0.75% (YoY)
2

With ROE of 34.50%, it has a fair valuation with a 11.63 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 32,048 Million (Large Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.79%

stock-summary
Debt Equity

-0.24

stock-summary
Return on Equity

34.50%

stock-summary
Price to Book

11.63

Revenue and Profits:
Net Sales:
833 Million
(Quarterly Results - Jun 2025)
Net Profit:
246 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.88%
0%
-3.88%
6 Months
8.95%
0%
8.95%
1 Year
11.57%
0%
11.57%
2 Years
74.48%
0%
74.48%
3 Years
111.87%
0%
111.87%
4 Years
185.84%
0%
185.84%
5 Years
105.74%
0%
105.74%

Xiamen Amoytop Biotech Co. Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
32.36%
EBIT Growth (5y)
49.44%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
1.11
Tax Ratio
10.37%
Dividend Payout Ratio
30.48%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
40.89%
ROE (avg)
22.33%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
11.63
EV to EBIT
30.11
EV to EBITDA
27.41
EV to Capital Employed
15.01
EV to Sales
10.05
PEG Ratio
0.74
Dividend Yield
0.79%
ROCE (Latest)
49.85%
ROE (Latest)
34.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 24.36% vs -21.95% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 34.98% vs -33.42% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "833.10",
          "val2": "669.90",
          "chgp": "24.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "298.90",
          "val2": "238.10",
          "chgp": "25.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "245.80",
          "val2": "182.10",
          "chgp": "34.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "326.90%",
          "val2": "315.80%",
          "chgp": "1.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 34.19% vs 37.52% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 49.01% vs 93.52% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,803.40",
          "val2": "2,089.10",
          "chgp": "34.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,023.40",
          "val2": "727.70",
          "chgp": "40.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.80",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.90",
          "val2": "-10.10",
          "chgp": "108.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "827.60",
          "val2": "555.40",
          "chgp": "49.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "331.70%",
          "val2": "315.70%",
          "chgp": "1.60%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
833.10
669.90
24.36%
Operating Profit (PBDIT) excl Other Income
298.90
238.10
25.54%
Interest
0.30
0.10
200.00%
Exceptional Items
0.60
0.00
Consolidate Net Profit
245.80
182.10
34.98%
Operating Profit Margin (Excl OI)
326.90%
315.80%
1.11%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 24.36% vs -21.95% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 34.98% vs -33.42% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,803.40
2,089.10
34.19%
Operating Profit (PBDIT) excl Other Income
1,023.40
727.70
40.63%
Interest
0.60
0.80
-25.00%
Exceptional Items
0.90
-10.10
108.91%
Consolidate Net Profit
827.60
555.40
49.01%
Operating Profit Margin (Excl OI)
331.70%
315.70%
1.60%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 34.19% vs 37.52% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 49.01% vs 93.52% in Dec 2023

stock-summaryCompany CV
About Xiamen Amoytop Biotech Co. Ltd. stock-summary
stock-summary
Xiamen Amoytop Biotech Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available